Brief: ImmuCell Pauses Investment In Re-Tain
24/12/2025 18:14
Dec 24 (Reuters) - ImmuCell Corp ICCC.O: EXPECTS NON-CASH IMPAIRMENT WRITE-DOWN FOR RE-TAIN DURING Q4 (REMOVES EXTRANEOUS WORD '$15.5 MILLION') IMMUCELL ANNOUNCES STRATEGIC FOCUS ON FIRST DEFENSE® AFTER RECEIVING AN FDA INCOMPLETE LETTER FOR RE-TAIN® PAUSES INVESTMENT IN RE-TAIN Further company coverage: ICCC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuCell
See all newsBrief: Immucell Announces A 46% Increase In Product Sales In Quarter Three Of 2026, Based On Preliminary, Unaudited Sales Results
ImmuCell Q2 revenue rises on higher distributor volume, price realization
Brief: ImmuCell Corporation Q2 EPS USD 0.2
ImmuCell Q2 product sales rise 11.5% on strong US demand
ImmuCell Q1 sales, profit rise on seasonal demand; to moderate mid-year